NCT03896009Phase 3Completed

Maximizing Outcomes in Treating Acute Migraine

Study sponsor: Axsome Therapeutics, Inc. · AXSM

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2019-12-10Actual

Enrollment · participants1594Actual

Source updated2023-08-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Migraine

Treatments or interventions studied

AXS-07 (MoSEIC meloxicam and rizatriptan)Drug
MeloxicamDrug
RizatriptanDrug
PlaceboDrug

Primary outcomes · main study measures

measure: Percentage of Subjects Reporting Headache Pain Freedom; description: Absence of headache pain. AXS-07 vs Placebo.; timeFrame: Hour 2 following dose administration; measure: Percentage of Subjects With Absence of Most Bothersome Symptom; description: Absence of most bothersome symptom, defined at the onset of migraine. AXS-07 vs Placebo.; timeFrame: Hour 2 following dose administration

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history